Niko Schmiedeberg

565 total citations
11 papers, 358 citations indexed

About

Niko Schmiedeberg is a scholar working on Oncology, Molecular Biology and Hematology. According to data from OpenAlex, Niko Schmiedeberg has authored 11 papers receiving a total of 358 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 5 papers in Molecular Biology and 5 papers in Hematology. Recurrent topics in Niko Schmiedeberg's work include Peptidase Inhibition and Analysis (6 papers), Blood Coagulation and Thrombosis Mechanisms (5 papers) and Protease and Inhibitor Mechanisms (5 papers). Niko Schmiedeberg is often cited by papers focused on Peptidase Inhibition and Analysis (6 papers), Blood Coagulation and Thrombosis Mechanisms (5 papers) and Protease and Inhibitor Mechanisms (5 papers). Niko Schmiedeberg collaborates with scholars based in Germany, Switzerland and United States. Niko Schmiedeberg's co-authors include Horst Kessler, Georg Martiny‐Baron, Pascal Furet, Jeanette M. Wood, Christian Schnell, Patricia Imbach, Philipp Holzer, Joseph Brueggen, Éric Billy and Viktor Magdolen and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Medicinal Chemistry and Organic Letters.

In The Last Decade

Niko Schmiedeberg

11 papers receiving 351 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Niko Schmiedeberg Germany 9 200 123 82 82 45 11 358
Durga Udayakumar United States 10 476 2.4× 175 1.4× 48 0.6× 53 0.6× 30 0.7× 25 625
Jacqueline Sayyah United States 9 368 1.8× 178 1.4× 17 0.2× 78 1.0× 29 0.6× 11 534
C. Zang Germany 8 283 1.4× 90 0.7× 19 0.2× 128 1.6× 21 0.5× 8 415
Matthew T. DiMare United States 6 190 0.9× 130 1.1× 35 0.4× 49 0.6× 46 1.0× 7 320
Bolormaa Baljinnyam United States 13 483 2.4× 111 0.9× 38 0.5× 84 1.0× 31 0.7× 25 611
P Tagliaferri Italy 7 305 1.5× 190 1.5× 27 0.3× 29 0.4× 38 0.8× 14 416
Paul Kwon United States 7 657 3.3× 169 1.4× 36 0.4× 42 0.5× 78 1.7× 9 728
Wun‐Shaing Wayne Chang Taiwan 10 196 1.0× 77 0.6× 11 0.1× 96 1.2× 38 0.8× 12 422
Jörg Mengwasser Germany 8 466 2.3× 131 1.1× 17 0.2× 46 0.6× 26 0.6× 12 587
Chu Myong Seong South Korea 12 360 1.8× 133 1.1× 13 0.2× 51 0.6× 32 0.7× 30 511

Countries citing papers authored by Niko Schmiedeberg

Since Specialization
Citations

This map shows the geographic impact of Niko Schmiedeberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Niko Schmiedeberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Niko Schmiedeberg more than expected).

Fields of papers citing papers by Niko Schmiedeberg

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Niko Schmiedeberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Niko Schmiedeberg. The network helps show where Niko Schmiedeberg may publish in the future.

Co-authorship network of co-authors of Niko Schmiedeberg

This figure shows the co-authorship network connecting the top 25 collaborators of Niko Schmiedeberg. A scholar is included among the top collaborators of Niko Schmiedeberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Niko Schmiedeberg. Niko Schmiedeberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Gurzeler, Lukas‐Adrian, Isabel Schmidt, Christian N. Parker, et al.. (2023). Drug-induced eRF1 degradation promotes readthrough and reveals a new branch of ribosome quality control. Cell Reports. 42(9). 113056–113056. 9 indexed citations
2.
Vulpetti, Anna, Philipp Holzer, Niko Schmiedeberg, et al.. (2023). Discovery of New Binders for DCAF1, an Emerging Ligase Target in the Targeted Protein Degradation Field. ACS Medicinal Chemistry Letters. 14(7). 949–954. 15 indexed citations
3.
Gutmann, Sascha, Alexandra Hinniger, Gabriele Fendrich, et al.. (2015). The Crystal Structure of Cancer Osaka Thyroid Kinase Reveals an Unexpected Kinase Domain Fold. Journal of Biological Chemistry. 290(24). 15210–15218. 14 indexed citations
4.
Högenauer, Klemens, Luca Arista, Niko Schmiedeberg, et al.. (2014). G-Protein-Coupled Bile Acid Receptor 1 (GPBAR1, TGR5) Agonists Reduce the Production of Proinflammatory Cytokines and Stabilize the Alternative Macrophage Phenotype. Journal of Medicinal Chemistry. 57(24). 10343–10354. 74 indexed citations
5.
Martiny‐Baron, Georg, Philipp Holzer, Éric Billy, et al.. (2010). The small molecule specific EphB4 kinase inhibitor NVP-BHG712 inhibits VEGF driven angiogenesis. Angiogenesis. 13(3). 259–267. 105 indexed citations
6.
7.
Schmiedeberg, Niko, Manfred Schmitt, Vincent Truffault, et al.. (2002). Synthesis, Solution Structure, and Biological Evaluation of Urokinase Type Plasminogen Activator (uPA)-Derived Receptor Binding Domain Mimetics. Journal of Medicinal Chemistry. 45(23). 4984–4994. 37 indexed citations
8.
Schmiedeberg, Niko, Michael D. Kramer, Fred C.G.J. Sweep, et al.. (2002). uPA-Silica-Particles (SP-uPA): A Novel Analytical System to Investigate uPA-uPAR Interaction and to Test Synthetic uPAR Antagonists as Potential Cancer Therapeutics. Biological Chemistry. 383(1). 207–16. 5 indexed citations
9.
Schmiedeberg, Niko & Horst Kessler. (2001). Reversible Backbone Protection Enables Combinatorial Solid-Phase Ring-Closing Metathesis Reaction (RCM) in Peptides. Organic Letters. 4(1). 59–62. 42 indexed citations
10.
Magdolen, Viktor, Niko Schmiedeberg, Florian R. Schroeck, et al.. (2001). Cyclo19,31[D-Cys19]-uPA19-31 Is a Potent Competitive Antagonist of the Interaction of Urokinase-Type Plasminogen Activator with Its Receptor (CD87). Biological Chemistry. 382(8). 1197–205. 29 indexed citations
11.
Muehlenweg, Bernd, Manfred Schmitt, Niko Schmiedeberg, et al.. (2000). Epitope Mapping of Monoclonal Antibodies Directed to PAI-1 Using PAI-1/PAI-2 Chimera and PAI-1-Derived Synthetic Peptides. Thrombosis Research. 98(1). 73–81. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Durga Udayakumar Breakdown of academic impact, for papers by Jacqueline Sayyah Breakdown of academic impact, for papers by C. Zang Breakdown of academic impact, for papers by Matthew T. DiMare Breakdown of academic impact, for papers by Bolormaa Baljinnyam Breakdown of academic impact, for papers by P Tagliaferri Breakdown of academic impact, for papers by Paul Kwon Breakdown of academic impact, for papers by Wun‐Shaing Wayne Chang Breakdown of academic impact, for papers by Jörg Mengwasser Breakdown of academic impact, for papers by Chu Myong Seong
Rankless by CCL
2026